Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share interests rather than a financial performance report.
Material Changes
On March 31, 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares and American Depository Shares (ADSs) for the service period of January 1, 2011, to March 31, 2011. The allocation price was set at £11.90 per Ordinary share and $38.34 per ADS. These allocations were communicated to the Company and the Directors on April 1, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Important Facts for Investors
- Allocation Date: Awards were provisionally allocated on March 31, 2011.
- Share Prices: Allocations were based on £11.90 per Ordinary share and $38.34 per ADS.
- Service Period: The awards cover the period from January 1, 2011, to March 31, 2011.
- Recipients: Awards were distributed to Non-Executive Directors including Sir Christopher Gent, Prof. Sir Roy Anderson, Dr Stephanie Burns, Mr Lawrence Culp, Sir Crispin Davis, Sir Deryck Maughan, Mr James Murdoch, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- Notification Timing: The Company and Directors were informed of these allocations on April 1, 2011.